← Back to headlines
Novartis Shares Drop After Late-Stage Neuromuscular Drug Trial Fails
Novartis saw its stock price fall sharply after announcing that a late-stage clinical trial for its del-desiran drug failed to meet its primary efficacy goal. The setback marks the third recent disappointment for the pharmaceutical company’s development pipeline.
8 Sept, 05:48 — 8 Sept, 07:51
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (71/100)8 sources33/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left2
Left (2)
cnbcindex-hr
Center5
Center (5)
FT20-minutenReutersinvesting-commorningstar
Right1
Right (1)
wsj
Far R
Geographic diversity— 5 regions21/34
US4UK1Switzerland1Croatia1Intl1
Sources
Showing 4 of 8 sources
ReutersVery High3h ago
Novartis faces fresh blow to pipeline with del-desiran drug setback - reuters.com
Novartis faces fresh blow to pipeline with del-desiran drug setback reuters.com
Read full article →cnbcMostly Factual1h ago
Pharma major plummets over 10% after third trial disappointment in a week
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Read full article →morningstar4h ago
Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial - Morningstar
Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial Morningstar
Read full article →investing-com3h ago
Novartis DM1 drug fails late-stage trial, clouding development outlook
By Investing.com
Read full article →Coverage Timeline
First report: morningstar · 8 Sept, 05:48|Full coverage: 8 · 3h|Window: 3h
Left-leaningCenterRight-leaning
Related Stories
Japanese Yen Rises to Seven-Month High on Rate Hike Expectations
42m ago
Volkswagen Weighs Sale of Motorcycle Maker Ducati in Portfolio Review
52m ago
China’s Exports Surge 25% in August, Trade Surplus Widens
1h ago
Singapore Airlines Defends Air India Investment, Adds Relief Flights for Krakatau Disruption
1h ago